Hey Paul, Remember this from OVER A YEAR AGO? G

Hey Paul, Remember this from OVER A YEAR AGO?

Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales
Force and Distribution Team for the Commercial Launch of Excellagen
- 150+ Wound care consultants the core of national launch of Excellagen for the treatment
of surgical wounds, diabetic foot ulcers, venous skin ulcers, and other hard to treat
wounds
- Contract with VA system through Service-Disabled Veteran-Owned Small Business
(SDVOSB) network
MIRAMAR, FL, December 20, 2018/PRNewswire/ -- Generex Biotechnology Corporation
(OTCQB:GNBT) is pleased to announce that their partially-owned, but soon to be wholly-owned
subsidiary, Olaregen Therapeutix has established a premier sales force in the wound care space
and contracted with a Service-Disabled Veteran-Owned Small Business (SDVOSB) for distribution
of Excellagen in the VA system through a network of veteran-owned distribution partners.
Olaregen CEO Anthony J. Dolisi commented, “Through a dedicated recruiting effort with our
sales channel partners, we are building an expert sales force with extensive experience in
medical sales and wound care. Olaregen now has 150+ Sales Consultants who are poised to
successfully commercialize Excellagen by delivering outstanding and connected customer
service. At Olaregen, we view customer support as an integral part of our mission to heal
challenging wounds with cutting-edge regenerative medicine products like Excellagen, which is
a novel cellular and tissue based product (CTP). CTPs are of particular benefit to chronic nonhealing wounds as they work to stimulate wound healing by utilizing the patient’s own cells to
rebuild tissues. We are pleased to have a dedicated sales force poised to launch Excellegen in
the multi-billion wound care market in the first quarter of 2019.”